Loading
KCND3 (A-type voltage-gated potassium channel KCND3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
Pore-forming (alpha) subunit of voltage-gated A-type potassium channels that mediates transmembrane potassium transport in excitable membranes, in brain and heart. In cardiomyocytes, may generate the transient outward potassium current I(To). In neurons, may conduct the transient subthreshold somatodendritic A-type potassium current (ISA).
Open Targets scores its association with cancer at 0.54 (direct and indirect evidence; datatypes literature 0.17, animal model 0.48, genetic association 0.36, clinical 0.76).
In plain words · KCND3 (A-type voltage-gated potassium channel KCND3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
KCND3 (A-type voltage-gated potassium channel KCND3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
Pore-forming (alpha) subunit of voltage-gated A-type potassium channels that mediates transmembrane potassium transport in excitable membranes, in brain and heart.
No product in this corpus aims at KCND3 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA KCND3: RNA tissue enhanced (brain 29 nTPM); no normal tissue stained high; highest cancer staining carcinoid (1 of 4 high). Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 1 specific cancer type at or above 0.5 (Lambert-Eaton myasthenic syndrome). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas KCND3 tissue; Open Targets ENSG00000171385 associations
First described 1998. Earliest sequence paper UniProt cites for the protein: Kong et al, Am. J. Physiol, 1998, "Isolation and characterization of the human gene encoding Ito: further diversity by alternative mRNA splicing". Source.
Sources: HGNC HGNC:6239 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9UK17 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000171385 (association with cancer (MONDO_0004992) 0.54; (GraphQL API, CC0))
Pore-forming (alpha) subunit of voltage-gated A-type potassium channels that mediates transmembrane potassium transport in excitable membranes, in brain and heart. In cardiomyocytes, may generate the transient outward potassium current I(To). In neurons, may conduct the transient subthreshold somatodendritic A-type potassium current (ISA). Kinetics properties are characterised by fast activation at subthreshold membrane potentials, rapid inactivation, and quick recovery from inactivation. Channel properties are modulated by interactions with regulatory subunits. Interaction with the regulatory subunits KCNIP1 or KCNIP2 modulates the channel gating kinetics namely channel activation and inactivation kinetics and rate of recovery from inactivation. Location: Cell membrane; Cell membrane, sarcolemma; Cell projection, dendrite (UniProt). Locus 1p13.2 (HGNC).
RNA: tissue enhanced (brain 29 nTPM), detected in many normal tissues.
No normal tissue stained high; medium in Adrenal gland, Appendix, Bone marrow, Breast, Bronchus, Caudate and more.
RNA cancer enhanced: Prostate Adenocarcinoma 12 pTPM.
Medium only: cervical cancer, colorectal cancer, endometrial cancer, glioma.
HPA KCND3 tissue · HPA KCND3 pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"KCND3" OR ABSTRACT:"KCND3" OR TITLE:"potassium voltage-gated channel subfamily D member 3" OR ABSTRACT:"potassium voltage-gated channel subfamily D member 3" OR TITLE:"A-type voltage-gated potassium channel KCND3" OR ABSTRACT:"A-type voltage-gated potassium channel KCND3" OR TITLE:"Kv4.3" OR ABSTRACT:"Kv4.3" OR TITLE:"KSHIVB" OR ABSTRACT:"KSHIVB" OR TITLE:"SCA22" OR ABSTRACT:"SCA22") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about KCND3, not a curated reading list.